Platelet function in health and disease: From molecular mechanisms, redox considerations to novel therapeutic opportunities

Antioxidants and Redox Signaling

Volumn 17, Issue 10, 2012, Pages 1447-1485

  Ferroni, Patrizia ^a   Vazzana, Natale ^b   Riondino, Silvia ^a   Cuccurullo, Chiara ^c   Guadagni, Fiorella ^a   Davì, Giovanni ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CALCIUM; CLOPIDOGREL; COLLAGEN RECEPTOR; FIBRINOGEN RECEPTOR; NITRIC OXIDE; PRASUGREL; PROSTAGLANDIN; PROTEINASE ACTIVATED RECEPTOR 1; REACTIVE OXYGEN METABOLITE; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; THROMBIN; TICAGRELOR; TICLOPIDINE; VORAPAXAR;

ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL WALL; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

ANIMALS; BLOOD PLATELETS; HUMANS; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84866271074     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4324     Document Type: Review

References (334)

1. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. Guidelines on platelet function testing. J Clin Pathol 41: 1322-1330, 1988.
2. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-1035, 1994.
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339, 1996.
4. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, and Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104: 1361-1368, 2004. (Pubitemid 39166512)
5. Albers GW, Amarenco P, Easton JD, Sacco RL, and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 630S-669S, 2008. (Pubitemid 351892974)
6. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, and Mitchell JA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J 20: 326-328, 2006. (Pubitemid 46671159)
7. Ali FY, Hall MG, Desvergne B, Warner TD, and Mitchell JA. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha-brief report. Arterioscler Thromb Vasc Biol 29: 1871-1873, 2009.
8. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, and Kubes P. Platelets express functional Toll-like receptor. Blood 106: 2417-2423, 2005. (Pubitemid 41510815)
9. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, and Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8: 247-252, 2002. (Pubitemid 34250102)
10. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetesmellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48: 298-304, 2006. (Pubitemid 44026661)
11. Angiolillo DJ, Capodanno D, and Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31: 17-28, 2010.
12. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, and Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54: 669-677, 2009.
13. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, Horvath IG, and Serebruany VL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160: 543-551, 2010.
14. Asch E and Podack E. Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 85: 1372-1378, 1990. (Pubitemid 20176428)
15. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, and Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100: 614-620, 1999. (Pubitemid 29379750)
16. Bachschmid M, Schildknecht S, and Ullrich V. Redox regulation of vascular prostanoid synthesis by the nitric oxidesuperoxide system. Biochem Biophys Res Commun 338: 536-542, 2005. (Pubitemid 41540600)
17. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860, 2009.
18. Bakdash N and Williams MS. Spatially distinct production of reactive oxygen species regulates platelet activation. Free Radic Biol Med 45: 158-166, 2008.
19. Balduini CL, Pecci A, and Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 154: 161-174, 2011.
20. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, and Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59: 295-302, 2003. (Pubitemid 36792384)
21. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, and Davi G. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48: 2531-2538, 2006. (Pubitemid 44881227)
22. Bath PM and Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7: 157-161, 1996. (Pubitemid 26167943)
23. Baumgartner HR. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha chymotrypsin-digested subendothelium. Thromb Haemost 37: 1-16, 1977. (Pubitemid 8059398)
24. Bava ED and Barber FA. Platelet-rich plasma products in sports medicine. Phys Sportsmed 39: 94-99, 2011.
25. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, and Harrington RA. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 776S-814S, 2008. (Pubitemid 351894917)
26. Benndorf RA, Schwedhelm E, Gnann A, Taheri R, Kom G, Didie M, Steenpass A, Ergun S, and Boger RH. Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ Res 103: 1037-1046, 2008.
27. Bernardi B, Guidetti GF, Campus F, Crittenden JR, Graybiel AM, Balduini C, and Torti M. The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2-beta1 and integrin alphaIIbbeta3. Blood 107: 2728-2735, 2006.
28. Beumer S, Heijnen HF, MJ IJ, Orlando E, de Groot PG, and Sixma JJ. Platelet adhesion to fibronectin in flow: the importance of von Willebrand factor and glycoprotein Ib. Blood 86: 3452-3460, 1995.
29. Bevers EM, Comfurius P, and Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 5: 146-154, 1991.
30. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 357: 2078-2081, 2007. (Pubitemid 350106717)
31. Bhatt DL and Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284: 1549-1558, 2000.
32. Blair P, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, Chakrabarti S, Hayashi C, Genco CA, Iafrati M, and Freedman JE. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res 104: 346-354, 2009.
33. Blann AD, Nadar SK, and Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24: 2166-2179, 2003. (Pubitemid 37522669)
34. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, SimeoniMC, Barragan P, Dignat-George F, and Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51: 1404-1411, 2008. (Pubitemid 351447314)
35. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56: 919-933, 2010.
36. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoue A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377: 2013-2022, 2011.
37. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, and Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153: 66. e9-16, 2007.
38. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58: 1945-1954, 2011.
39. Brass LF. Thrombin and platelet activation. Chest 124: 18S-25S, 2003. (Pubitemid 37128432)
40. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303: 754-762, 2010.
41. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
42. Calvo D, Gomez-Coronado D, Lasuncion MA, and Vega MA. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol 17: 2341-2349, 1997. (Pubitemid 28015966)
43. Calzada C, Vericel E, and Lagarde M. Decrease in platelet reduced glutathione increases lipoxygenase activity and decreases vitamin E. Lipids 26: 696-699, 1991.
44. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, MiccoliM,Marchesini J, Bernardi F, Ferrari R, and Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57: 2474-2483, 2011.
45. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, and Storey RF. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50: 1844-1851, 2007. (Pubitemid 350007959)
46. Carafoli E. Calcium pump of the plasma membrane. Physiol Rev 71: 129-153, 1991.
47. Carter MJ, Fylling CP, and Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty 11: e38, 2011.
48. Catella F, Healy D, Lawson JA, and FitzGerald GA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 83: 5861-5865, 1986. (Pubitemid 16000613)
49. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24: 1980-1987, 2004. (Pubitemid 39482419)
50. Cattaneo M. ADP receptors antagonists. In: Platelets, edited by Michelson AD. San Diego, CA: Academic Press, 2007, pp. 1127-1144.
51. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 35: 158-167, 2009.
52. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, and Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 7: 1029, 2009.
53. Cattaneo M and Podda GM. State of the art of new P2Y12 antagonists. Intern Emerg Med 5: 385-391, 2010.
54. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51: 3061-3064, 2008. (Pubitemid 351821864)
55. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, and Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 25: 2428-2434, 2005. (Pubitemid 41552666)
56. Chen K, Febbraio M, Li W, and Silverstein RL. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ Res 102: 1512-1519, 2008.
57. Chen WH, Lee PY, Ng W, Tse HF, and Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43: 1122-1126, 2004. (Pubitemid 38353000)
58. Cheng K, Malliaras K, Shen D, Tseliou E, Ionta V, Smith J, Galang G, Sun B, Houde C, and Marban E. Intramyocardial injection of platelet gel promotes endogenous repair and augments cardiac function in rats with myocardial infarction. J Am Coll Cardiol 59: 256-264, 2012.
59. Chintala M, Vemulapalli S, Kurowski S, Sabin C, Reynolds D, Prevete K, and Friedrich G. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 28: e138-e139, 2008.
60. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, and Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 8: 148-156, 2010.
61. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, and Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 992: 66-70, 1989. (Pubitemid 19179025)
62. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91: 3527-3561, 1998. (Pubitemid 28225719)
63. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13: 463-469, 2007. (Pubitemid 46559832)
64. Clemetson KJ and Clemetson JM. Platelet collagen receptors. Thromb Haemost 86: 189-197, 2001. (Pubitemid 32663952)
65. Coleman RA, Smith WL, and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229, 1994. (Pubitemid 24185151)
66. Collaboration. AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002.
67. Coller BS and Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112: 3011-3025, 2008.
68. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96: 11023-11027, 1999. (Pubitemid 29487321)
69. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 86: 298-307, 2001. (Pubitemid 32663960)
70. Cox D and McConkey S. The role of platelets in the pathogenesis of cerebral malaria. Cell Mol Life Sci 67: 557-568, 2010.
71. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, and de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-A systematic review. Thromb Haemost 99: 14-26, 2008.
72. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, Housman DE, and Graybiel AM. CalDAGGEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 10: 982-986, 2004. (Pubitemid 39273740)
73. Croce K and Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 14: 55-61, 2007. (Pubitemid 44885613)
74. da Costa Martins PA, van Gils JM, Mol A, Hordijk PL, and Zwaginga JJ. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol 79: 499-507, 2006. (Pubitemid 44831227)
75. Dachary-Prigent J, Pasquet JM, Freyssinet JM, and Nurden AT. Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2 +-ATPase inhibitors. Biochemistry 34: 11625-11634, 1995.
76. Daniel JL, Dangelmaier C, and Smith JB. Evidence for a role for tyrosine phosphorylation of phospholipase C gamma 2 in collagen-induced platelet cytosolic calcium mobilization. Biochem J 302 (Pt 2): 617-622, 1994. (Pubitemid 24280121)
77. Davi G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, and Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 85: 1792-1798, 1992.
78. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, and Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322: 1769-1774, 1990. (Pubitemid 20194655)
79. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, and Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107: 3199-3203, 2003. (Pubitemid 36793091)
80. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229, 1999. (Pubitemid 29056363)
81. Davi G and Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 14: 760-764, 2005. (Pubitemid 41413307)
82. Davi G, Falco A, and Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 128: 149-163, 2004. (Pubitemid 38167384)
83. Davi G, Ganci A, Averna M, Giammarresi C, Barbagallo C, Catalano I, Cala A, and Notarbartolo A. Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Haemost 74: 1015-1019, 1995.
84. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, and Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96: 69-75, 1997. (Pubitemid 27298406)
85. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, and Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288: 2008-2014, 2002. (Pubitemid 35204691)
86. Davi G and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357: 2482-2494, 2007.
87. Davi G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, and Bittolo Bon G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 97: 953-957, 1998. (Pubitemid 28125466)
88. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, and Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 339: b4531, 2009.
89. De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, Landolfi R, Patrono C, and Davi G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 1: 250-256, 2003.
90. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, and Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85: 2284-2290, 1992.
91. de la Llera-Moya M, Rothblat GH, Connelly MA, Kellner-Weibel G, Sakr SW, Phillips MC, and Williams DL. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 40: 575-580, 1999. (Pubitemid 29116161)
92. Dent JA, Galbusera M, and Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 88: 774-782, 1991.
93. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, and Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 88: 146-157, 1996. (Pubitemid 26230682)
94. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, and Gurbel PA. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56: 3014-3019, 2007. (Pubitemid 350223637)
95. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, and Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331-337, 2004.
96. Dixon LJ, Hughes SM, Rooney K, Madden A, Devine A, Leahey W, Henry W, Johnston GD, and McVeigh GE. Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am J Hypertens 18: 839-843, 2005. (Pubitemid 40745271)
97. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, et al. The contribution of cyclooxygenase-1 and-2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 115: 1054-1061, 2010.
98. Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr Opin Hematol 14: 262-269, 2007. (Pubitemid 46597613)
99. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650-1655, 2002. (Pubitemid 34298607)
100. Eikelboom JW and O'Donnell M. Using aspirin to prevent cognitive decline. BMJ 337: a958, 2008.
101. Essex DW. The role of thiols and disulfides in platelet function. Antioxid Redox Signal 6: 736-746, 2004. (Pubitemid 38890791)
102. Essex DW, Li M, Miller A, and Feinman RD. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry 40: 6070-6075, 2001. (Pubitemid 32466310)
103. Everts PA, Knape JT, Weibrich G, Schonberger JP, Hoffmann J, Overdevest EP, Box HA, and van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol 38: 174-187, 2006. (Pubitemid 351506605)
104. Ezumi Y, Shindoh K, Tsuji M, and Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med 188: 267-276, 1998. (Pubitemid 28357755)
105. Ferroni P, Basili S, Falco A, and Davi G. Oxidant stress and platelet activation in hypercholesterolemia. Antioxid Redox Signal 6: 747-756, 2004. (Pubitemid 38890792)
106. Ferroni P, Martini F, Riondino S, La Farina F, Magnapera A, Ciatti F, and Guadagni F. Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta 399: 88-91, 2009.
107. Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, and Busse R. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 90: 863-871, 2003. (Pubitemid 37427856)
108. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5: 338-349, 2008. (Pubitemid 351761708)
109. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 459: 923-939, 2010.
110. Forstermann U, Nakane M, Tracey WR, and Pollock JS. Isoforms of nitric oxide synthase: functions in the cardiovascular system. Eur Heart J 14 Suppl I: 10-15, 1993. (Pubitemid 23362587)
111. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol 28: s11-s16, 2008.
112. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, and Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350-356, 1997. (Pubitemid 27349081)
113. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, and Wagner DD. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 191: 1413-1422, 2000. (Pubitemid 30227127)
114. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42: 227-276, 2011.
115. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99: 466-472, 2008. (Pubitemid 351549282)
116. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, and Daniel WG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104: 2395-2400, 2001. (Pubitemid 33108370)
117. Gawaz M, Langer H, and May AE. Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378-3384, 2005. (Pubitemid 43121822)
118. Giannarelli C, Zafar MU, and Badimon JJ. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism? Thromb Haemost 104: 949-954, 2010.
119. Gibbins JM, Okuma M, Farndale R, Barnes M, and Watson SP. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett 413: 255-259, 1997. (Pubitemid 27353279)
120. Gkaliagkousi E, Ritter J, and Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ Res 101: 654-662, 2007. (Pubitemid 47494096)
121. Godyna S, Diaz-Ricart M, and Argraves WS. Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood 88: 2569-2577, 1996. (Pubitemid 26327507)
122. Goodwin DC, Gunther MR, Hsi LC, Crews BC, Eling TE, Mason RP, and Marnett LJ. Nitric oxide trapping of tyrosyl radicals generated during prostaglandin endoperoxide synthase turnover. Detection of the radical derivative of tyrosine 385. J Biol Chem 273: 8903-8909, 1998. (Pubitemid 28235692)
123. Goto S, Ikeda Y, Saldivar E, and Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 101: 479-486, 1998. (Pubitemid 28067346)
124. Gray SJ and Heptinstall S. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP. Eur J Pharmacol 194: 63-70, 1991.
125. Gresele P, Catalano M, Giammarresi C, Volpato R, Termini R, Ciabattoni G, Nenci GG, and Davi G. Platelet activation markers in patients with peripheral arterial disease-a prospective comparison of different platelet function tests. Thromb Haemost 78: 1434-1437, 1997. (Pubitemid 27519385)
126. Gresele P, Cerletti C, Guglielmini G, Pignatelli P, de Gaetano G, and Violi F. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem 22: 201-211, 2011.
127. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, and Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50: 1822-1834, 2007. (Pubitemid 350007957)
128. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, and Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52: 743-749, 2008.
129. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, and Kleiman NS. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5: 490-496, 2007. (Pubitemid 46680680)
130. Hamberg M, Svensson J, and Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994-2998, 1975.
131. Harper MT and Poole AW. Store-operated calcium entry and non-capacitative calcium entry have distinct roles in thrombin-induced calcium signalling in human platelets. Cell Calcium 50: 351-358, 2011.
132. Harrison D, Griendling KK, Landmesser U, Hornig B, and Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 91: 7A-11A, 2003. (Pubitemid 36351457)
133. Harrison P. Platelet function analysis. Blood Rev 19: 111-123, 2005. (Pubitemid 39643116)
134. Harrison P. Assessment of platelet function in the laboratory. Hamostaseologie 29: 25-31, 2009.
135. Harrison P and Keeling D. Clinical tests of platelet function. In: Platelets, 2nd ed., edited by Michelson AD. San Diego, CA: Elsevier/Academic Press, 2007, pp. 445-447.
136. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, and Machin S. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 155: 30-44, 2011.
137. Hattori Y, Suzuki M, Hattori S, and Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 46: 1543-1549, 2003. (Pubitemid 37518575)
138. Hayward CP and Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 33: 273-282, 2007. (Pubitemid 46581382)
139. Hayward CP, Harrison P, Cattaneo M, Ortel TL, and Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4: 312-319, 2006.
140. Heemskerk JW, Bevers EM, and Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 88: 186-193, 2002. (Pubitemid 34873696)
141. Heemskerk JW, Kuijpers MJ, Munnix IC, and Siljander PR. Platelet collagen receptors and coagulation. A characteristic platelet response as possible
142. Heemskerk JW, Willems GM, Rook MB, and Sage SO. Ragged spiking of free calcium in ADP-stimulated human platelets: regulation of puff-like calcium signals in vitro and ex vivo. J Physiol 535: 625-635, 2001. (Pubitemid 32894476)
143. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, and Simoons ML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348: 1104-1111, 2003. (Pubitemid 36337321)
144. Hekimsoy Z, Payzin B, Ornek T, and Kandogan G. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications 18: 173-176, 2004. (Pubitemid 38622547)
145. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, and Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594, 1998. (Pubitemid 28157601)
146. Higashi Y, Noma K, Yoshizumi M, and Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 73: 411-418, 2009.
147. Hindriks G, Ijsseldijk MJ, Sonnenberg A, Sixma JJ, and de Groot PG. Platelet adhesion to laminin: role of Ca2 + and Mg2 + ions, shear rate, and platelet membrane glycoproteins. Blood 79: 928-935, 1992.
148. Hoffman M and Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 85: 958-965, 2001. (Pubitemid 32573743)
149. Hollander JE, Muttreja MR, Dalesandro MR, and Shofer FS. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol 34: 95-105, 1999.
150. Horstman LL and Ahn YS. Platelet microparticles: a wideangle perspective. Crit Rev Oncol Hematol 30: 111-142, 1999.
151. Huang MM, Bolen JB, Barnwell JW, Shattil SJ, and Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci USA 88: 7844-7848, 1991. (Pubitemid 21915251)
152. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, and Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27: 1038-1047, 2006.
153. Inoue O, Suzuki-Inoue K, Dean WL, Frampton J, and Watson SP. Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 160: 769-780, 2003. (Pubitemid 36298271)
154. Jackson MR. Fibrin sealants in surgical practice: an overview. Am J Surg 182: 1S-7S, 2001. (Pubitemid 32898601)
155. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11: 507-514, 2005. (Pubitemid 40685973)
156. Jaumdally RJ, Varma C, Blann AD, MacFadyen RJ, and Lip GY. Platelet activation in coronary artery disease: intracardiac vs peripheral venous levels and the effects of angioplasty. Chest 132: 1532-1539, 2007. (Pubitemid 350156010)
157. Jennings I, Woods TA, Kitchen S, and Walker ID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants. J Clin Pathol 61: 950-954, 2008.
158. Jennings LK, Earhart A, Becker RC, Reyderman L, Veltri E, and Harrington RA. Thrombin receptor antagonist (TRA;SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics. Circulation 116: II674, 2007.
159. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138: 152-163, 2001. (Pubitemid 32812228)
160. Jin J, Daniel JL, and Kunapuli SP. Molecular basis for ADPinduced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273: 2030-2034, 1998. (Pubitemid 28069249)
161. Jinchuan Y, Zonggui W, Jinming C, Li L, and Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 339: 85-90, 2004. (Pubitemid 37542461)
162. Jung SM and Moroi M. Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha(2)beta(1). J Biol Chem 275: 8016-8026, 2000. (Pubitemid 30159713)
163. Jurk K, Clemetson KJ, de Groot PG, Brodde MF, Steiner M, Savion N, Varon D, Sixma JJ, Van Aken H, and Kehrel BE. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 17: 1490-1492, 2003.
164. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, and Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103: 879-887, 1999. (Pubitemid 29152634)
165. Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, and Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 102: 1701-1707, 2003. (Pubitemid 37022563)
166. Kato Y, Kita Y, Hirasawa-Taniyama Y, Nishio M, Mihara K, Ito K, Yamanaka T, Seki J, Miyata S, and Mutoh S. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 473: 163-169, 2003. (Pubitemid 36929880)
167. Katopodis JN, Kolodny L, Jy W, Horstman LL, De Marchena EJ, Tao JG, Haynes DH, and Ahn YS. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol 54: 95-101, 1997. (Pubitemid 27079414)
168. Keane C, Tilley D, Cunningham A, Smolenski A, Kadioglu A, Cox D, Jenkinson HF, and Kerrigan SW. Invasive Streptococcus pneumoniae trigger platelet activation via Toll-like receptor 2. J Thromb Haemost 8: 2757-2765, 2010.
169. Keaney JF Jr., Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, and Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23: 434-439, 2003. (Pubitemid 36337219)
170. Kerrigan SW, Clarke N, Loughman A, Meade G, Foster TJ, and Cox D. Molecular basis for Staphylococcus aureusmediated platelet aggregate formation under arterial shear in vitro. Arterioscler Thromb Vasc Biol 28: 335-340, 2008. (Pubitemid 351161208)
171. Kerrigan SW and Cox D. Platelet-bacterial interactions. Cell Mol Life Sci 67: 513-523, 2010.
172. Kerrigan SW, Douglas I, Wray A, Heath J, Byrne MF, Fitzgerald D, and Cox D. A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. Blood 100: 509-516, 2002. (Pubitemid 34761113)
173. Khazaei M, Moien-Afshari F, and Laher I. Vascular endothelial function in health and diseases. Pathophysiology 15: 49-67, 2008.
174. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, and Bray PF. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 95: 2289-2296, 2000. (Pubitemid 30167727)
175. Klovaite J, Benn M, Yazdanyar S, and Nordestgaard BG. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost 9: 49-56, 2010.
176. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108: 793-797, 2001. (Pubitemid 32880286)
177. Krotz F, Sohn HY, and Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 24: 1988-1996, 2004. (Pubitemid 39482420)
178. Kushner FG, Hand M, Smith S Jr., King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With STElevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120: 2271-2306, 2009.
179. Lahav J, Gofer-Dadosh N, Luboshitz J, Hess O, and Shaklai M. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Lett 475: 89-92, 2000. (Pubitemid 30365056)
180. Lahav J, Jurk K, Hess O, Barnes MJ, Farndale RW, Luboshitz J, and Kehrel BE. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 100: 2472-2478, 2002.
181. Langer HF and Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 99: 480-486, 2008. (Pubitemid 351549284)
182. Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, and Furie B. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 59: 305-312, 1989. (Pubitemid 19264376)
183. Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, and Ahn YS. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 72: 295-304, 1993. (Pubitemid 23329372)
184. Leiva A, Verdejo H, Benitez ML, Martinez A, Busso D, and Rigotti A. Mechanisms regulating hepatic SR-BI expression and their impact on HDL metabolism. Atherosclerosis 217: 299-307, 2011.
185. Levy-Toledano S. Platelet signal transduction pathways: could we organize them into a 'hierarchy'? Haemostasis 29: 4-15, 1999. (Pubitemid 29446368)
186. Li Z, Delaney MK, O'Brien KA, and Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30: 2341-2349, 2010.
187. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, and Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 278: 30725-30731, 2003. (Pubitemid 36994579)
188. Liao JK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation 115: 1615-1621, 2007. (Pubitemid 46648647)
189. Libby P and Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 103: 1718-1720, 2001. (Pubitemid 32291406)
190. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, and Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 154: 485-490, 2001. (Pubitemid 34286155)
191. Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, and Saldeen T. Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr 77: 700-706, 2003. (Pubitemid 36258583)
192. Liu Y, Bubolz AH, Mendoza S, Zhang DX, and Gutterman DD. H2O2 is the transferrable factor mediating flow-induced dilation in human coronary arterioles. Circ Res 108: 566-573, 2011.
193. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, and Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28: 1702-1708, 2007. (Pubitemid 47227104)
194. Lova P, Paganini S, Hirsch E, Barberis L, Wymann M, Sinigaglia F, Balduini C, and Torti M. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. J Biol Chem 278: 131-138, 2003. (Pubitemid 36043554)
195. Lowenberg EC, Meijers JC, and Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 68: 242-251, 2010.
196. Malinin A, Pokov A, Swaim L, Kotob M, and Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28: 315-322, 2006. (Pubitemid 44047198)
197. Marcus AJ, Silk ST, Safier LB, and Ullman HL. Superoxide production and reducing activity in human platelets. J Clin Invest 59: 149-158, 1977. (Pubitemid 8018050)
198. Maschberger P, Bauer M, Baumann-Siemons J, Zangl KJ, Negrescu EV, Reininger AJ, and Siess W. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2 + influx in human platelets. J Biol Chem 275: 19159-19166, 2000. (Pubitemid 30422886)
199. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196: 887-896, 2002.
200. May JM. How does ascorbic acid prevent endothelial dysfunction? Free Radic Biol Med 28: 1421-1429, 2000. (Pubitemid 30621484)
201. McCarty OJ, Larson MK, Auger JM, Kalia N, Atkinson BT, Pearce AC, Ruf S, Henderson RB, Tybulewicz VL, Machesky LM, et al. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem 280: 39474-39484, 2005. (Pubitemid 41713905)
202. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, and Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 84: 92-99, 1989. (Pubitemid 19170099)
203. McFarland JG. Laboratory investigation of drug-induced immune thrombocytopenias. Transfus Med Rev 7: 275-287, 1993. (Pubitemid 23297291)
204. Mega JL, Simon T,Collet JP,Anderson JL,AntmanEM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. Reducedfunction CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304: 1821-1830, 2010.
205. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 103: 20A-26A, 2009.
206. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, and Valeri CR. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 93: 11877-11882, 1996. (Pubitemid 26347217)
207. Michelson AD, Linden M, Barnard MR, Furman MI, and Frelinger AL. Flow cytometry. In: Platelets, edited by Michelson AD. San Diego, CA: Academic Press, 2007, pp. 545-563.
208. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, and Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res 92: e31-e40, 2003.
209. Montuschi P, Barnes PJ, and Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 18: 1791-1800, 2004. (Pubitemid 39602265)
210. Moro L, Reineri S, Piranda D, Pietrapiana D, Lova P, Bertoni A, Graziani A, Defilippi P, Canobbio I, Torti M, et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood 105: 115-121, 2005. (Pubitemid 40053072)
211. MorrowJD. Is oxidant stress a connection between obesity and atherosclerosis? Arterioscler Thromb Vasc Biol 23: 368-370, 2003. (Pubitemid 36337207)
212. Morrow JD, Awad JA, Boss HJ, Blair IA, and Roberts LJ 2nd. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 89: 10721-10725, 1992.
213. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, and Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87: 9383-9387, 1990. (Pubitemid 120030630)
214. Morrow JD and Roberts LJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 166: S25-S30, 2002. (Pubitemid 36015933)
215. Murthy M, Rao GH, Robinson P, and Reddy S. Influx of extracellular calcium and agonist-coupling appear essential for the activation of thromboxane A2-dependent phospholipase A2 in human platelets. Prostaglandins Leukot Essent Fatty Acids 53: 31-39, 1995.
216. Musiek ES, Yin H, Milne GL, and Morrow JD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 40: 987-994, 2005.
217. Narumiya S, Sugimoto Y, and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193-1226, 1999. (Pubitemid 29473315)
218. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, and Fassler R. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 20: 2120-2130, 2001. (Pubitemid 32410582)
219. Nomura S, Komiyama Y, Miyake T, Miyazaki Y, Kido H, Suzuki M, Kagawa H, Yanabu M, Takahashi H, and Fukuhara S. Amyloid beta-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 72: 519-522, 1994. (Pubitemid 24305642)
220. O'Brien LM, Walsh EJ, Massey RC, Peacock SJ, and Foster TJ. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 4: 759-770, 2002. (Pubitemid 35378715)
221. Pandey D, Goyal P, Dwivedi S, and Siess W. Unraveling a novel Rac1-mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin-stimulated platelets. Blood 114: 415-424, 2009.
222. Patrono C. Measurement of thromboxane biosynthesis in man. Eicosanoids 2: 249-251, 1989.
223. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330: 1287-1294, 1994. (Pubitemid 24129964)
224. Patrono C, Baigent C, Hirsh J, and Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S, 2008. (Pubitemid 351894914)
225. Patrono C, Ciabattoni G, and Davi G. Thromboxane biosynthesis in cardiovascular diseases. Stroke 21 (12 Suppl): IV130-133, 1990.
226. Patrono C and FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17: 2309-2315, 1997. (Pubitemid 28015962)
227. Patrono C, Garcia Rodriguez LA, Landolfi R, and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373-2383, 2005. (Pubitemid 41713749)
228. Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, and Chap H. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 60: 1069-1074, 2000.
229. Peerschke EI. Regulation of platelet aggregation by postfibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Thromb Haemost 73: 862-867, 1995.
230. Philipose S, Konya V, Sreckovic I, Marsche G, Lippe IT, Peskar BA, Heinemann A, and Schuligoi R. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 30: 2416-2423, 2010.
231. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, and Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 110: 1326-1329, 2004. (Pubitemid 39202353)
232. Pignatelli P, Sanguigni V, Paola SG, Lo Coco E, Lenti L, and Violi F. Vitamin C inhibits platelet expression of CD40 ligand. Free Radic Biol Med 38: 1662-1666, 2005. (Pubitemid 40726072)
233. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13: 1086-1095, 2007. (Pubitemid 47517507)
234. Prasad KS, Andre P, He M, Bao M, Manganello J, and Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 100: 12367-12371, 2003. (Pubitemid 37271566)
235. Pratico D, Lawson JA, Rokach J, and FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 12: 243-247, 2001. (Pubitemid 33714213)
236. Pratico D, Rokach J, Lawson J, and FitzGerald GA. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 128: 165-171, 2004. (Pubitemid 38167385)
237. Pratico D, Smyth EM, Violi F, and FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 271: 14916-14924, 1996.
238. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, and Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124: 1132-1137, 2011.
239. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305: 1097-1105, 2011.
240. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, and Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29: 992-1000, 2008. (Pubitemid 351844676)
241. Queen LR, Xu B, Horinouchi K, Fisher I, and Ferro A. beta(2)- adrenoceptors activate nitric oxide synthase in human platelets. Circ Res 87: 39-44, 2000. (Pubitemid 30456933)
242. RadomskiMW, Palmer RM, andMoncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87: 5193-5197, 1990.
243. Randriamboavonjy V and Fleming I. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there? Pharmacol Rep 57 Suppl: 59-65, 2005.
244. Ray DM, Spinelli SL, Pollock SJ, Murant TI, O'Brien JJ, Blumberg N, Francis CW, Taubman MB, and Phipps RP. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost 99: 86-95, 2008.
245. Reilly IA and FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69: 180-186, 1987. (Pubitemid 17007095)
246. Reiner AP, Carlson CS, Thyagarajan B, Rieder MJ, Polak JF, Siscovick DS, Nickerson DA, Jacobs DR Jr., and Gross MD. Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol 28: 1549-1555, 2008.
247. Ren Q, Ye S, and Whiteheart SW. The platelet release reaction: just when you thought platelet secretion was simple. Curr Opin Hematol 15: 537-541, 2008.
248. Rey C, Vericel E, Nemoz G, Chen W, Chapuy P, and Lagarde M. Purification and characterization of glutathione peroxidase from human blood platelets. Age-related changes in the enzyme. Biochim Biophys Acta 1226: 219-224, 1994. (Pubitemid 24182468)
249. Ridker PM, Buring JE, and Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103: 491-495, 2001. (Pubitemid 32116231)
250. Riondino S, Martini F, La Farina F, Spila A, Guadagni F, and Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem 43: 666-670, 2010.
251. Rivera J, Lozano ML, Navarro-Nunez L, and Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 94: 700-711, 2009.
252. Rocca B and Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 3: 1597-1602, 2005. (Pubitemid 41716544)
253. Rosado JA, Brownlow SL, and Sage SO. Endogenously expressed Trp1 is involved in store-mediated Ca2 + entry by conformational coupling in human platelets. J Biol Chem 277: 42157-42163, 2002. (Pubitemid 35257533)
254. Rosado JA, Lopez JJ, Harper AG, Harper MT, Redondo PC, Pariente JA, Sage SO, and Salido GM. Two pathways for store-mediated calcium entry differentially dependent on the actin cytoskeleton in human platelets. J Biol Chem 279: 29231-29235, 2004. (Pubitemid 38915798)
255. Rosado JA and Sage SO. Platelet signaling: calcium. In: Platelets in Thrombotic And Non-Thrombotic Disorders. Cambridge University Press, 2002, pp. 260-271.
256. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 120 Suppl 1: S5-S9, 2007. (Pubitemid 46874544)
257. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 16: 58-83, 2009.
258. Ruggeri ZM, Dent JA, and Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 94: 172-178, 1999. (Pubitemid 29300146)
259. Ruggeri ZM, Orje JN, Habermann R, Federici AB, and Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 108: 1903-1910, 2006. (Pubitemid 44394999)
260. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359: 1238-1251, 2008.
261. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67: 395-424, 1998. (Pubitemid 28411134)
262. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, and Violi F. Shortterm treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111: 412-419, 2005. (Pubitemid 40204424)
263. Santilli F, Basili S, Ferroni P, and Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2: 256-268, 2007.
264. Santilli F, Davi G, Basili S, Lattanzio S, Cavoni A, Guizzardi G, De Feudis L, Traisci G, Pettinella C, Paloscia L, et al. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost 8: 914-922, 2010.
265. Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, et al. Thromboxane- dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47: 391-397, 2006. (Pubitemid 43063260)
266. Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattoni G, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 8: 828-837, 2010.
267. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 53: 667-677, 2009.
268. Savage B, Saldivar E, and Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84: 289-297, 1996. (Pubitemid 26040846)
269. Scharf RE, Rahman MM, and Seidel H. The impact and management of acquired platelet dysfunction. Hamostaseologie 31: 28-40, 2011.
270. Schildknecht S, van der Loo B, Weber K, Tiefenthaler K, Daiber A, and Bachschmid MM. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic Biol Med 45: 512-520, 2008.
271. Schonbeck U, Varo N, Libby P, Buring J, and Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 104: 2266-2268, 2001. (Pubitemid 33049505)
272. Schwedhelm E, Bierend A, Maas R, Trinks R, Kom GD, Tsikas D, and Boger RH. Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease. J Thromb Haemost 8: 2662-2670, 2010.
273. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, and Bhatt DL. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 102: 111-119, 2009.
274. Sharma G and Berger JS. Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. J Thromb Thrombolysis 32: 201-208, 2011.
275. Shattil SJ,Hoxie JA,CunninghamM,andBrass LF.Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem260: 11107-11114, 1985. (Pubitemid 16253272)
276. Shattil SJ, Kashiwagi H, and Pampori N. Integrin signaling: the platelet paradigm. Blood 91: 2645-2657, 1998. (Pubitemid 28227512)
277. Shattil SJ and Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104: 1606-1615, 2004. (Pubitemid 39202265)
278. Shaw KT, Mawji Y, Stevenson MM, and Kongshavn PA. Cells within the vascular system capable of mediating trypanocidal activity in vitro. Infect Immun 59: 3143-3150, 1991.
279. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, and von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53: 849-856, 2009.
280. Sibbing D, Byrne RA, Bernlochner I, and Kastrati A. High platelet reactivity and clinical outcome-fact and fiction. Thromb Haemost 106: 191-202, 2011.
281. Signorello MG, Pascale R, and Leoncini G. Transport of Larginine and nitric oxide formation in human platelets. Eur J Biochem 270: 2005-2012, 2003. (Pubitemid 36560822)
282. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, and Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375, 2009.
283. Singla A, Antonino MJ, Bliden KP, Tantry US, and Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 158: 784.e781-e786, 2009.
284. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, and Coller BS. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 99: 620-625, 1999. (Pubitemid 29077360)
285. Smith SC Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363-2372, 2006. (Pubitemid 43947981)
286. Soulet C, Gendreau S, Missy K, Benard V, Plantavid M, and Payrastre B. Characterisation of Rac activation in thrombinand collagen-stimulated human blood platelets. FEBS Lett 507: 253-258, 2001. (Pubitemid 33030245)
287. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, MoliternoDJ,Navetta FI, Berger PB, Popma JJ,DangasG, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103: 2572-2578, 2001. (Pubitemid 32521967)
288. Stenberg PE, McEver RP, Shuman MA, Jacques YV, and Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 101: 880-886, 1985. (Pubitemid 16256841)
289. Stokes KY, Calahan L, Hamric CM, Russell JM, and Granger DN. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol 296: H689-H697, 2009.
290. Stokes KY, Calahan L, Russell JM, Gurwara S, and Granger DN. Role of platelets in hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction. Microcirculation 13: 377-388, 2006. (Pubitemid 44028440)
291. Stokes KY, Russell JM, Jennings MH, Alexander JS, and Granger DN. Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic Biol Med 43: 22-30, 2007. (Pubitemid 46874832)
292. Strassel C, Moog S, Baas MJ, Cazenave JP, and Lanza F. Biosynthesis of platelet glycoprotein V expressed as a single subunit or in association with GPIb-IX. Eur J Biochem 271: 3671-3677, 2004. (Pubitemid 39233609)
293. Suzuki-Inoue K, Yatomi Y, Asazuma N, Kainoh M, Tanaka T, Satoh K, and Ozaki Y. Rac, a small guanosine triphosphate-binding protein, and p21-activated kinase are activated during platelet spreading on collagen-coated surfaces: roles of integrin alpha(2)beta(1). Blood 98: 3708-3716, 2001.
294. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, Ginsberg MH, and Calderwood DA. Talin binding to integrin beta tails: a final common step in integrin activation. Science 302: 103-106, 2003. (Pubitemid 37210697)
295. Terada LS. Specificity in reactive oxidant signaling: think globally, act locally. J Cell Biol 174: 615-623, 2006.
296. Thomas SR, Witting PK, and Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 10: 1713-1765, 2008.
297. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, and Gries FA. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 17: 433-438, 1991.
298. Tsiara S, Elisaf M, Jagroop IA, and Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 9: 177-190, 2003. (Pubitemid 37070125)
299. Urbich C, Dernbach E, Aicher A, Zeiher AM, and Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106: 981-986, 2002. (Pubitemid 34925334)
300. Ussar S, Wang HV, Linder S, Fassler R, and Moser M. The Kindlins: subcellular localization and expression during murine development. Exp Cell Res 312: 3142-3151, 2006. (Pubitemid 44292664)
301. Valiyaveettil M, Kar N, Ashraf MZ, Byzova TV, Febbraio M, and Podrez EA. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 111: 1962-1971, 2008. (Pubitemid 351451506)
302. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007. (Pubitemid 44566469)
303. Vallance P and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24: 1023-1030, 2004. (Pubitemid 38737826)
304. Van de Walle GR, Schoolmeester A, Iserbyt BF, Cosemans JM, Heemskerk JW, Hoylaerts MF, Nurden A, Vanhoorelbeke K, and Deckmyn H. Activation of alphaIIbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets. Blood 109: 595-602, 2007. (Pubitemid 46105957)
305. van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, and Nieuwland R. P-selectin-and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 52: 657-664, 2006.
306. Varga-Szabo D, Braun A, and Nieswandt B. Calcium signaling in platelets. J Thromb Haemost 7: 1057-1066, 2009.
307. Varga-Szabo D, Pleines I, and Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 28: 403-412, 2008.
308. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernandez-Cruz A, Veves A, Jarolim P, Varo JJ, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107: 2664-2669, 2003. (Pubitemid 36667238)
309. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, Hoekstra M, Sierts JA, Dallinga-Thie GM, Motazacker MM, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 364: 136-145, 2011.
310. Vidal C, Spaulding C, Picard F, Schaison F, Melle J, Weber S, and Fontenay-RoupieM. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 86: 784-790, 2001. (Pubitemid 32834186)
311. Vizioli L, Muscari S, and Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 63: 1509-1515, 2009.
312. von Hundelshausen P, and Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100: 27-40, 2007. (Pubitemid 46066771)
313. Wall JE, Buijs-Wilts M, Arnold JT, Wang W, White MM, Jennings LK, and Jackson CW. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 89: 380-385, 1995.
314. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057, 2009.
315. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376: 1320-1328, 2010.
316. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, Block PC, Block EH, Ladenheim M, and Simon DI. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92: 1492-1494, 2003. (Pubitemid 37532584)
317. Wang TH, Bhatt DL, and Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27: 647-654, 2006.
318. Wang Z, Ciabattoni G, Creminon C, Lawson J, Fitzgerald GA, Patrono C, and Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 275: 94-100, 1995.
319. Watson SP, Auger JM, McCarty OJ, and Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 3: 1752-1762, 2005. (Pubitemid 41716562)
320. Weiss HJ, Sussman II, and Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with vonWillebrand's disease. J Clin Invest 60: 390-404, 1977. (Pubitemid 8154146)
321. Weitz JI, Hirsh J, and Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 234S-256S, 2008. (Pubitemid 351892968)
322. Weyrich AS and Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 25: 489-495, 2004. (Pubitemid 39490256)
323. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015, 2007. (Pubitemid 350106708)
324. Woulfe DS. Platelet G protein-coupled receptors in hemostasis and thrombosis. J Thromb Haemost 3: 2193-2200, 2005. (Pubitemid 41727197)
325. Woulfe DS. Akt signaling in platelets and thrombosis. Expert Rev Hematol 3: 81-91, 2010.
326. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, and Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23: 712-719, 2003. (Pubitemid 36566157)
327. Yee DL, Sun CW, Bergeron AL, Dong JF, and Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106: 2723-2729, 2005. (Pubitemid 41510746)
328. Zarbock A, Polanowska-Grabowska RK, and Ley K. Platelet-neutrophil- interactions: linking hemostasis and inflammation. Blood Rev 21: 99-111, 2007. (Pubitemid 46428465)
329. Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, and Koksch M. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 11: 723-728, 2000. (Pubitemid 32010206)
330. Zhang G, Han J, Welch EJ, Ye RD, Voyno-Yasenetskaya TA, Malik AB, Du X, and Li Z. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 182: 7997-8004, 2009.
331. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta PC, Ramadas K, Tsugane S, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med 364: 719-729, 2011.
332. Zou MH and Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett 382: 101-104, 1996. (Pubitemid 26092944)
333. Zwaal RF and Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89: 1121-1132, 1997. (Pubitemid 27079974)
334. Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML, and Frangogiannis NG. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol 48: 2315-2323, 2006. (Pubitemid 44855440)